Pittsburgh-based Astria Biosciences has received a U.S. patent for a whole-blood diagnostic test capable of detecting cerebral aneurysms, assessing rupture risk, and monitoring patient status after treatment — using only a standard blood draw. "Very excited to share that our patent for whole blood, mini-proteomic, diagnostic test for cerebral aneurysm detection and stratification US-12553904-B2 is […]

Only subscribers get to read this.

Hit SUBSCRIBE for freemium or paid content access.